Insilico approach of interaction studies in Bacopa monnieri compounds targeting multi-proteins for Alzheimer's Disease

Bacopa monnieri Linn (plantaginaceae) is perennial, creeping herb native to the wetlands of southern and eastern India, Australia, Europe and Asia. It is a well-known medicinal plant, is widely used in traditional medicine system in the treatment of epilepsy, asthma, gastrointestinal discomfort, skin disease and has antimicrobial action, antioxidant and anticancer. It is a nootropic and used as memory enhancer and reducing anxiety in the treatment of attention deficit hyperactivity disorder. Bacopa monnieri (also known as Brahmi) is used in the treatment of Alzheimer’s disease. The objective of this study was to establish the binding energy of Bacopa monnieri biological active compounds and drug likeliness by Insilico techniques for treatment of Alzheimer’s disease with CASP3. The compounds taken were apigenin, rosavin and luteolin. These compounds are docked
by using AutoDock 4.2 Software with proteins selected based upon the literature survey and the PDB IDs are 5IAS, 5IAR, 5IAJ, and 5IBC. From the docking results the compounds shows satisfactory dock score values respectively. These compounds are visualized by using Discovery studio 4.1 Visualizer followed by DruLiTo software which satisfies the Lipinski’s properties for all the compounds. This result depicts the Bacopa monneri derivatives having significant role to design new compounds with these properties for treating Alzheimer’s
disease.